20.06

2.76% -0.57

After Hours: 20.00 -0.06 -0.30%

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $20.06, with a volume of 2.85M. It is down -2.76% in the last 24 hours and down -15.71% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Previous Close:

$20.63

Open:

$20.96

24h Volume:

2.85M

Relative Volume:

1.43

Market Cap:

$3.38B

Revenue:

$890.53M

Net Income/Loss:

$30.57M

P/E Ratio:

111.44

EPS:

0.18

Net Cash Flow:

$80.53M

1W Performance:

-7.98%

1M Performance:

-15.71%

6M Performance:

+42.17%

1Y Performance:

+37.87%

1-Day Range:

$20.02

$20.96

1-Week Range:

$20.02

$21.95

52-Week Range:

$13.40

$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1140)

Industry

Biotechnology (637)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

654

Twitter

@acadiapharma

Next Earnings Date

2024-11-06

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD Acadia Pharmaceuticals Inc	20.06	3.48B	890.53M	30.57M	80.53M	0.18
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-25	Upgrade	Deutsche Bank	Hold → Buy
Feb-11-25	Initiated	Deutsche Bank	Hold
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

Oct 12, 2025

How to track smart money flows in ACADIA Pharmaceuticals Inc.Portfolio Value Report & Risk Managed Trade Strategies - newser.com

Oct 12, 2025

Oct 10, 2025

Why ACADIA Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & Safe Entry Zone Identification - newser.com

Oct 10, 2025

Leerink Partnrs Issues Optimistic Outlook for ACAD Earnings - MarketBeat

Oct 10, 2025

Heatmap analysis for ACADIA Pharmaceuticals Inc. and competitors2025 Pullback Review & Weekly Market Pulse Alerts - newser.com

Oct 10, 2025

How high can ACADIA Pharmaceuticals Inc. stock go2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 10, 2025

Detecting support and resistance levels for ACADIA Pharmaceuticals Inc.2025 Macro Impact & Verified Momentum Watchlists - newser.com

Oct 10, 2025

Applying Elliott Wave Theory to ACADIA Pharmaceuticals Inc.IPO Watch & Expert Curated Trade Ideas - newser.com

Oct 10, 2025

Oct 09, 2025

Using Bollinger Bands to evaluate ACADIA Pharmaceuticals Inc.July 2025 Momentum & AI Enhanced Execution Alerts - newser.com

Oct 09, 2025

Oct 08, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire

Oct 08, 2025

Q3 EPS Estimate for ACADIA Pharmaceuticals Cut by Analyst - MarketBeat

Oct 08, 2025

RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating - MarketScreener

Oct 08, 2025

Oct 07, 2025

Acadia Healthcare Company, Inc. Announces Chief Financial Officer Changes, Effective October 27, 2025 - MarketScreener

Oct 07, 2025

What drives ACADIA Pharmaceuticals Inc stock priceHead and Shoulders Patterns & Double Digit Capital Growth - earlytimes.in

Oct 07, 2025

Oct 06, 2025

How to interpret RSI for ACADIA Pharmaceuticals Inc. stockWeekly Risk Summary & Reliable Intraday Trade Alerts - newser.com

Oct 06, 2025

Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Volume Spike & Weekly Chart Analysis and Trade Guides - newser.com

Oct 06, 2025

Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AI2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com

Oct 06, 2025

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) - Seeking Alpha

Oct 06, 2025

Is ACADIA Pharmaceuticals Inc. stock attractive after correctionRate Hike & Weekly High Conviction Ideas - newser.com

Oct 06, 2025

Wealth Enhancement Advisory Services LLC Makes New $511,000 Investment in ACADIA Pharmaceuticals Inc. $ACAD - Defense World

Oct 06, 2025

Oct 05, 2025

Intraday pattern recognizer results for ACADIA Pharmaceuticals Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com

Oct 05, 2025

Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWall Street Watch & Reliable Intraday Trade Alerts - newser.com

Oct 05, 2025

News impact scoring models applied to ACADIA Pharmaceuticals Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com

Oct 05, 2025

What machine learning models say about ACADIA Pharmaceuticals Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com

Oct 05, 2025

Will ACADIA Pharmaceuticals Inc. rebound enough to break even2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com

Oct 05, 2025

Oct 04, 2025

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study - MSN

Oct 04, 2025

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 04, 2025

Oct 03, 2025

ACADIA Pharmaceuticals Inc. Securities Lawsuit Investigation - Claim Depot

Oct 03, 2025

Using flow based indicators on ACADIA Pharmaceuticals Inc.Weekly Loss Report & High Conviction Trade Alerts - newser.com

Oct 03, 2025

A Look at Acadia Pharmaceuticals’s Valuation After Setback in Phase 3 Prader-Willi Trial - Sahm

Oct 03, 2025

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - BioSpace

Oct 03, 2025

Published on: 2025-10-03 03:21:29 - newser.com

Oct 03, 2025

Acadia to present pipeline updates at Parkinson’s congress By Investing.com - Investing.com Nigeria

Oct 03, 2025

Oct 02, 2025

Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions - Fierce Pharma

Oct 02, 2025

Acadia to present pipeline updates at Parkinson’s congress - Investing.com

Oct 02, 2025

Upcoming Events - FinancialContent

Oct 02, 2025

Oct 01, 2025

ATTENTION ACADIA Pharmaceuticals Inc. (ACAD) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Oct 01, 2025